congress
presentations

American Association of Neurology (AAN) 2024 Annual Meeting

Denver, CO
April 13-18, 2024

PDF screenshot

AXS-05 | Alzheimer's Disease Agitation

CLINICAL TRIALS PLENARY SESSION (Tuesday, April 16 from 9:15 a.m. to 11:30 a.m. MT): Efficacy and Safety Of AXS-05 in Alzheimer’s Disease Agitation: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Study

view/download

PDF screenshot

AXS-07 | Migraine

EMERGE Study: An Open-Label Evaluation of the Efficacy and Safety of AXS-07 (MoSEIC™ Meloxicam and Rizatriptan) for Migraine in Adults With Prior Inadequate Response to an Oral CGRP Inhibitor

view/download

PDF screenshot

AXS-07 | Migraine

Combined Efficacy and Safety of AXS-07 (MoSEIC™ Meloxicam and Rizatriptan) in Two Phase 3 Clinical Trials

view/download

PDF screenshot

Solriamfetol | Excessive Daytime Sleepiness

Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-Controlled Study of Sleep Apnea Participants (SHARP)

view/download

PDF screenshot

Solriamfetol | Excessive Daytime Sleepiness

Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea: Effect Sizes and Numbers Needed to Treat or Harm

view/download

PDF screenshot

Solriamfetol | Excessive Daytime Sleepiness

SURWEY Study of Solriamfetol: Initiation, Titration, Safety, Efficacy, and Follow-Up Experience for Patients with OSA in Germany

view/download

This site is intended for registered attendees of the respective Congress.
This site contains scientific presentations on investigational products and/or investigational uses of approved products for Axsome or its partners sponsored studies.
The safety and efficacy of investigational products and/or investigational uses of approved products has not been established and such investigational products/uses have not and may not be approved for marketing by any health authority.
Marketing authorization, approval status, and prescribing information for approved products varies by country. Please seek further details from the health authority in your country such as approved product labeling.

AXSOME and its logos are trademarks or registered trademarks of Axsome Therapeutics, Inc. or its affiliates. Other trademarks are property of their respective owners.

© 2023 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, 22nd Floor, New York, NY 10007 info@axsome.com